1. 561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation. (10th December 2020) Authors: Muik, Alexander; Altintas, Isil; Kosoff, Rachelle; Gieseke, Friederike; Schödel, Kristina; Salcedo, Theodora; Burm, Saskia; Toker, Aras; Kranz, Lena; Vormehr, Mathias; Eisel, David; Fereshteh, Mark; Türeci, Özlem; Breij, Esther; Ahmadi, Tahamtan; Sahin, Ugur; Jure-Kunkel, Maria Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A338 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation. (9th November 2020) Authors: Muik, Alexander; Altintas, Isil; Kosoff, Rachelle; Gieseke, Friederike; Schödel, Kristina; Salcedo, Theodora; Burm, Saskia; Toker, Aras; Kranz, Lena; Vormehr, Mathias; Eisel, David; Fereshteh, Mark; Türeci, Özlem; Breij, Esther; Ahmadi, Tahamtan; Sahin, Ugur; Jure-Kunkel, Maria Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A595 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 704 Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3x5T4 in vitro and in vivo in solid cancer models. (9th November 2020) Authors: Kemper, Kristel; Gielen, Ellis; Houtkamp, Mischa; Boross, Peter; Burm, Saskia; Poot, Stefanie De; Engelberts, Patrick; Goeij, Bart de; Satijn, David; Sasser, Kate; Breij, Esther Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A746 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 704 Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3x5T4 in vitro and in vivo in solid cancer models. (9th November 2020) Authors: Kemper, Kristel; Gielen, Ellis; Houtkamp, Mischa; Boross, Peter; Burm, Saskia; Poot, Stefanie De; Engelberts, Patrick; Goeij, Bart de; Satijn, David; Sasser, Kate; Breij, Esther Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A423 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. C1q potentiates DR5 agonist activity by a mixture of two DR5-specific HexaBody® molecules. (October 2018) Authors: Beurskens, Frank; Overdijk, Marije; Strumane, Kristin; Buijsse, Antonio Ortiz; Vermot-Desroches, Claudine; Kroes, Thessa; de Jong, Bart; Hoevenaars, Naomi; de Jong, Rob; Lingnau, Andreas; Parren, Paul; Schuurman, Janine; Breij, Esther Journal: Molecular immunology Issue: Volume 102(2018:Oct.) Page Start: 134 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Hexamerization-enhanced CD37 and CD20 antibodies synergize in CDC to kill patient-derived CLL cells with unprecedented potency. (October 2018) Authors: Taylor, Ronald; Lindorfer, Margaret; Oostindie, Simone; Cook, Erika; Zent, Clive; Burack, Richard; Beurskens, Frank; Schuurman, Janine; Breij, Esther; Parren, Paul Journal: Molecular immunology Issue: Volume 102(2018:Oct.) Page Start: 218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗